Articles

Elotuzumab plus Bortezomib and Dexamethasone versus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 2 Study (CA204-009T)
ASH 2015 – Multiple Myeloma
Researchers presented 2-year follow-up safety and efficacy results of a phase 2 open-label study that compared the efficacy and safety of combination therapy with the anti-SLAM7 monoclonal antibody elotuzumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma (RRMM). Read More ›
All-Oral Combination of Ixazomib/Cyclophosphamide/Low-Dose Dexamethasone (ICd) in Transplant-Ineligible Newly Diagnosed MM
ASH 2015 – Multiple Myeloma
Researchers report the results of a phase 2 study evaluating the tolerability and long-term outcomes using a combination of ixazomib plus cyclophosphamide and low-dose dexamethasone in newly diagnosed multiple myeloma (MM) patients who are not eligible for transplant. Read More ›
Long-Term Follow-Up of the HOVON-65/GMMG-HD4 Trial of Bortezomib Induction and Maintenance in Patients with Newly Diagnosed MM
ASH 2015 – Multiple Myeloma
Researchers report the significant and lasting improvement in progression-free survival and overall survival in patients treated with bortezomib. A subgroup analysis identified bortezomib to have an effect on the high-risk effects of del(17p) and renal impairment on survival. Read More ›
Elotuzumab plus Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory MM: ELOQUENT-2 Trial Update
ASH 2015 – Multiple Myeloma
In a phase 3 study, researchers assessed the safety and efficacy of elotuzumab plus lenalidomide/dexamethasone, the first immunostimulatory monoclonal antibody for the treatment of relapsed/refractory multiple myeloma. Here, they report 3-year follow-up data. Read More ›

Page 124 of 147


© Amplity, Inc. All Rights Reserved. Privacy Policy